Neuphoria Therapeutics (NEUP) Intangibles (2020 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Intangibles of $4.3 million for Q1 2026, down 13.33% year-over-year from $5.0 million in Q1 2025, and down 3.7% quarter-over-quarter from $4.5 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Intangibles (2020 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Intangibles for 7 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles fell 13.33% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (down 13.33% YoY), while the FY2025 annual figure was $4.8 million, down 12.12% from the prior year.
- Intangibles eased to $4.3 million in Q1 2026 per NEUP's latest filing, from $4.5 million in the prior quarter.
- Across five years, Intangibles topped out at $7.0 million in Q2 2022 and bottomed at $4.3 million in Q1 2026.
- Historically, Intangibles has averaged $5.4 million across 5 years, with a median of $5.3 million in 2024.
- Annual changes were most pronounced in 2022 — Intangibles surged 823.07% — and 2026, when it slipped 13.33%.
- Neuphoria Therapeutics' Intangibles stood at $7.0 million in 2022, then dropped by 17.71% to $5.8 million in 2023, then retreated by 11.43% to $5.1 million in 2024, then decreased by 12.9% to $4.5 million in 2025, then decreased by 3.7% to $4.3 million in 2026.
- Business Quant data shows NEUP's Intangibles at $4.3 million in Q1 2026, $4.5 million in Q4 2025, and $4.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 93.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | 4.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.31 Mn |
| Dec 31, 2025 | 4.47 Mn |
| Sep 30, 2025 | 4.64 Mn |
| Jun 30, 2025 | 4.80 Mn |
| Mar 31, 2025 | 4.97 Mn |
| Dec 31, 2024 | 5.14 Mn |
| Sep 30, 2024 | 5.30 Mn |
| Jun 30, 2024 | 5.47 Mn |
| Mar 31, 2024 | 5.63 Mn |
| Dec 31, 2023 | 5.80 Mn |
| Sep 30, 2023 | 5.96 Mn |
| Jun 30, 2023 | 6.15 Mn |
| Jun 30, 2022 | 7.05 Mn |
| Jun 30, 2021 | -974,574.09 |
| Jun 30, 2020 | -1.01 Mn |